In fact, Fang et al. [45] reported that treatment with trametinib (MEK inhibitor) plus palbociclib (CDK4/6 inhibitor) resulted in a G0/G1 cell cycle arrest and apoptotic cell death in HNSCC cells, along with a remarkable decrease of MAPK pathway activation. This evidence concerns the gene MAP2K7 and head and neck squamous cell carcinoma.